Although pan-FGFR inhibitors like erdafitinib are effective for BLCA with FGFR3 mutations/fusions, their efficacy is limited for FGFR1-dependent tumors (44, 47). This evidence concerns the gene FGFR1 and bladder transitional cell carcinoma.